戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uggesting that rV10 may serve as an improved plague vaccine.
2 lla flagellin as an adjuvant in an acellular plague vaccine.
3 ndidate for development of an effective anti-plague vaccine.
4 target for developing an effective pneumonic plague vaccine.
5 ve antigen proposed for inclusion in subunit plague vaccines.
6 but should not be exposed to live-attenuated plague vaccines.
7 YopE could be a valuable addition to subunit plague vaccines and provide a new animal model in which
8                               At present, no plague vaccines are available for use in the United Stat
9                       Currently, no licensed plague vaccines are available in the Western world.
10 f-adjuvanting Y. pestis OMVs provide a novel plague vaccine candidate and that the rational design of
11                                      Several plague vaccine candidates are currently at various stage
12 ew correlate of protection for evaluation of plague vaccine candidates.
13 e human immune response to a new recombinant plague vaccine, comprising recombinant F1 (rF1) and rV a
14    Mice delivered with a single dose of F1-V plague vaccine containing both gene and protein in the T
15                                      Subunit plague vaccines containing the Y. pestis F1 and LcrV pro
16 sinia pseudotuberculosis strain as a type of plague vaccine could diversify prophylactic choices and
17                   Current efforts to develop plague vaccines focus on LcrV, a polypeptide that reside
18        This work demonstrates that a subunit plague vaccine formulated for human use provides signifi
19  tested and developed into a live attenuated plague vaccine(s).
20 tis challenge, and we suggest that pneumonic plague vaccines should aim to induce mixed type 1 and ty
21     These observations strongly suggest that plague vaccines should strive to maximally prime both ce
22 rongly suggest that development of pneumonic plague vaccines should strive to prime both CD4 and CD8
23 ar Typhi strain to create a bivalent mucosal plague vaccine that produces both the protective F1 caps
24  aid the development of a safe and effective plague vaccine, we are investigating roles for T cells d
25   As a first step in formulating an improved plague vaccine, we developed a simple purification strat
26  a part of a project to develop a plant-made plague vaccine, we expressed our model antigen, the Yers
27  a part of a project to develop a plant-made plague vaccine, we expressed the Yersinia pestis F1-V an
28  development of safe and effective pneumonic plague vaccines, we are deciphering mechanisms used by t